Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.

Autor:	Takahashi K; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan., Uozumi R; Department of Industrial Engineering and Economics, Tokyo Institute of Technology, Tokyo, Japan., Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Hayashida T; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Iwabe M; Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan., Iihara H; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Kusuhara-Mamishin K; Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan., Kitagawa Y; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Tsuchiya M; Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan., Kitahora M; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Nagayama A; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Kosaka S; Department of Surgery, National Hospital Organization Mito Medical Center, Ibaraki, Japan., Asano-Niwa Y; Department of Breast Surgery, Gifu University Hospital, Gifu, Japan., Seki T; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Ohnuki K; Department of Breast Surgery, Miyagi Cancer Center, Miyagi, Japan., Suzuki A; Department of Pharmacy, Gifu University Hospital, Gifu, Japan., Ono F; Department of Surgery, Keio University School of Medicine, Tokyo, Japan., Futamura M; Department of Breast Surgery, Gifu University Hospital, Gifu, Japan., Kawazoe H; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan., Nakamura T; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. e741-e749.
DOI:	10.1093/oncolo/oyae015
Abstrakt:	Background: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment. Patients and Methods: This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio. Results: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups. Conclusion: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted. (© The Author(s) 2024. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu